Health, Biotechnology and Life Sciences
+39 06 50576077
via Castel Romano 100 - 00128 Roma
Takis is a biotechnology company based in Rome, founded in 2009 by a group of scientists from Merck Research Laboratories (MRL) to develop cancer immunotherapy solutions, aiming to the generation of therapeutic vaccines.
The group has more than 10 years of experience in drug discovery and is recognized for the conception and implementation of a number of innovative technologies with the goal to improve in vivo gene transfer, regulation of gene expression and immunogenicity. Takis has developed a proprietary vaccine technology based on DNA ElectroGeneTransfer to induce potent immune responses against a variety of Antigens. POC of the technology successfully achieved for Cancer Vaccines in Phase 1 trials in humans. Takis has a diverse pipeline of projects based on DNA ElectroGeneTransfer ranging from Cancer, Malaria, and monoclonal antibodies. COVID-eVax is a vaccine against COVID-19 currently in PhaseI/II clinical trial planned to go on the market on 1Q22. In addition, Takis provides specialized Research and Development services to Pharmaceutical companies, Biotech and Academia.